Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy - Full Text View - ClinicalTrials.gov

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy - Full Text View - ClinicalTrials.gov

Shanghai cancer drug maker nets $171 million in Series B

Shanghai-based Haihe Biopharma has raised $171 million in its latest financing round, which was led by private equity firm Warburg Pincus.

The oncology-focused Chinese drug developer has a pipeline of 11 compounds: three are in pre-clinical studies and another three are in active Phase 3 trials. Haihe's sole product on the market is Liporaxel, an oral form of paclitaxel chemotherapy, co-developed with South Korea's Daehwa Pharma. It is approved in Korea for gastric cancer and is currently in late-stage trials in China for metastatic breast cancer.